Skip to main content
S&P 5007,656.98+0.86%DOW52,573.29+0.98%NASDAQ26,333.03+0.96%BTC$77,792.00+1.42%ETH$2,500.84+1.09%GOLD$4,300.20-2.47%OIL$104.24+4.19%
Smart Investors Daily
TE

NASDAQ · TELA

TELA Bio, Inc.

Healthcare · Medical - Devices

$0.97

Up+$0.06 (+7.17%)

Updated Sep 14, 2026, 12:17 PM

SID Score

5.2/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
45.56M
P/E ratio
-1.32
Dividend yield
0.00%
52-week range
$0.50 – $1.27
Volume
254.21K
Avg. volume
183.24K

Price performance

TELA price history

1M range · 19 trading sessions · Daily adjusted prices

TELA closed at $0.97 after 19 trading sessions, up 49.23% for the selected period.

Last close
$0.97
Period change
+49.23%
Period low
$0.64
Period high
$0.97
Daily close
View OHLC price history
TELA OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 11, 2026$0.8879$0.9873$0.85$0.97254.21K
Sep 10, 2026$0.9054$0.9054$0.8511$0.9051130.28K
Sep 9, 2026$0.83$0.94$0.83$0.9113298.29K
Sep 8, 2026$0.8499$0.87$0.8114$0.8301121.41K
Sep 4, 2026$0.794$0.8433$0.7899$0.8215115.65K
Sep 3, 2026$0.75$0.92$0.75$0.781522.63K
Sep 2, 2026$0.771$0.83$0.739$0.7524129.08K
Sep 1, 2026$0.721$0.839$0.721$0.7913300.52K
Aug 31, 2026$0.68$0.85$0.68$0.738533.97K
Aug 28, 2026$0.668$0.70$0.6501$0.70124.08K
Aug 27, 2026$0.6701$0.7002$0.639$0.65134.38K
Aug 26, 2026$0.679$0.6996$0.6539$0.691161.97K
Aug 25, 2026$0.65$0.70$0.65$0.70131.26K
Aug 24, 2026$0.6561$0.6561$0.6229$0.6542.07M
Aug 21, 2026$0.6799$0.6801$0.6251$0.646359.8K
Aug 20, 2026$0.659$0.6799$0.6303$0.639395.96K
Aug 19, 2026$0.66$0.6699$0.6035$0.647119.04K
Aug 18, 2026$0.65$0.689$0.616$0.643297.02K
Aug 17, 2026$0.64$0.6913$0.622$0.65241.52K

Latest TELA news

The latest Smart Investors Daily articles mentioning TELA.

Stock researchCompany · Overview

TELA research

Overview

Company profile and research snapshot.

Company profile

TELA Bio Inc a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. Its growing product portfolio is purposefully designed to leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. The company's OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$2.42
Implied upside
—
Analysts
—
TELA recent ratings
DateFirmRatingTarget
Mar 27, 2026CitizensMarket Outperform—
Mar 25, 2026Lake StreetBuy—
Mar 25, 2026Piper SandlerNeutral—
Mar 25, 2026Canaccord GenuityBuy—
Dec 1, 2025Lake StreetBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Aug 31, 2026

TELA Bio Announces COO / CFO Transition and Strategic Cost Reduction Initiative

Company to reduce annual operating expenses by $17.0 million or 18% as part of broader efficiency programMALVERN, Pa., Aug. 31, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA Bio” or the “Company”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that Roberto Cuca, Chief Operating Officer and Chief Financial Officer, will step down from the role effective today. “On behalf of the Board and management team, I woul

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By